JD Supra: FDA finalizes 2025 Q-Submission Guidance, streamlining interactions for device sponsors and proposes electronic submission mandate for Q-Submissions using eStar
FDA finalizes 2025 Q-Submission Guidance, streamlining interactions for device sponsors and proposes electronic submission mandate for Q-Submissions using eStar
The US Food and Drug Administration (FDA) has released a new draft guidance describing what should and should not be included in the Drug Interactions (DIs) section for human prescription drug and ...
The US Food and Drug Administration (FDA) on Thursday finalized two guidances providing recommendations to drugmakers on evaluating potential drug-drug interactions (DDIs) for new drugs through ...
EurekAlert!: Scientists re-writes an equation in FDA guidance to improve the accuracy of the drug interaction prediction
Scientists re-writes an equation in FDA guidance to improve the accuracy of the drug interaction prediction
RAPS: FDA releases draft guidance for drug interaction studies with combined oral contraceptives
The US Food and Drug Administration (FDA) has issued draft guidance for industry on performing clinical studies to look at the potential interactions between an investigational drug and combined oral ...
FDA releases draft guidance for drug interaction studies with combined oral contraceptives
Please provide your email address to receive an email when new articles are posted on . The Infectious Diseases Society of America issued guidance to help clinicians manage drug interactions between ...
FierceBiotech: Comparison Between the Final FDA, PMDA, and EMA In Vitro Drug Interaction Guidance
Expert drug-drug interaction (DDI) insights into potential development challenges presented by the current in vitro guidance documents and how to harmonize your strategies to meet the expectations of ...
Comparison Between the Final FDA, PMDA, and EMA In Vitro Drug Interaction Guidance